First test of new cancer drug in humans begins
NCT ID NCT05263739
Summary
This was an early-stage trial to test the safety and find the right dose of a new drug called ESG206 for adults with advanced B-cell blood cancers like lymphoma. The study was for people whose cancer had worsened despite standard treatments and who had no other good options. Researchers planned to give increasing doses to small groups of patients to see how their bodies handled the drug and to check for any early signs it might help fight the cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for B-CELL LYMPHOID MALIGNANCIES are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.